Emojevwe Victory Aghogho, Arman Shahriari, H. Mahboobi
{"title":"Navigating the Gut-Brain Axis: Insights into the Pathogenesis of Hepatic Encephalopathy","authors":"Emojevwe Victory Aghogho, Arman Shahriari, H. Mahboobi","doi":"10.2174/0126662906301568240427100342","DOIUrl":null,"url":null,"abstract":"\n\nHepatic encephalopathy is a neurological condition that affects people who have an insufficient\nliver function. However, its pathophysiology is yet unclear. For hepatic encephalopathy,\npharmacotherapy is the primary treatment choice. Lowering ammonia levels, enhancing neurotransmitter\nsignal transduction, and modifying gut microbiota, tackles the pathophysiology of hepatic\nencephalopathy. The intestinal microbiota of liver disease patients differs greatly from that of\nhealthy people, and this difference is linked to the development of hepatic encephalopathy. Additionally,\ngut microbiota is intimately linked to several theories in the pathophysiology of hepatic\nencephalopathy, such as the GABA-ergic tone hypothesis, bile acid circulation, ammonia poisoning\ntheory, and neuroinflammation, all of which exacerbate patients' cognitive and motor impairments.\nProviding some probiotics or reestablishing the intestinal bacteria's balance has a substantial\nimpact on neurological illnesses in hepatic encephalopathy. The goal of this review is to determine\nthe possible metabolic impacts and microbiological pathways in the gut-brain axis mediated progression\nof hepatic encephalopathy, as well as its potential function as a therapeutic target.\n","PeriodicalId":125135,"journal":{"name":"The International Journal of Gastroenterology and Hepatology Diseases","volume":"89 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The International Journal of Gastroenterology and Hepatology Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126662906301568240427100342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hepatic encephalopathy is a neurological condition that affects people who have an insufficient
liver function. However, its pathophysiology is yet unclear. For hepatic encephalopathy,
pharmacotherapy is the primary treatment choice. Lowering ammonia levels, enhancing neurotransmitter
signal transduction, and modifying gut microbiota, tackles the pathophysiology of hepatic
encephalopathy. The intestinal microbiota of liver disease patients differs greatly from that of
healthy people, and this difference is linked to the development of hepatic encephalopathy. Additionally,
gut microbiota is intimately linked to several theories in the pathophysiology of hepatic
encephalopathy, such as the GABA-ergic tone hypothesis, bile acid circulation, ammonia poisoning
theory, and neuroinflammation, all of which exacerbate patients' cognitive and motor impairments.
Providing some probiotics or reestablishing the intestinal bacteria's balance has a substantial
impact on neurological illnesses in hepatic encephalopathy. The goal of this review is to determine
the possible metabolic impacts and microbiological pathways in the gut-brain axis mediated progression
of hepatic encephalopathy, as well as its potential function as a therapeutic target.